Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

Diagnostic Microbiology and Infectious Disease

Volumn 52, Issue 3, 2005, Pages 203-208

  Sader, Helio S ^a   Jones, Ronald N ^a,b   Dowzicky, Michael J ^c   Fritsche, Thomas R ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Acinetobacter spp.; Antimicrobial resistance; Intensive care unit; Nosocomial infections

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD FLOW; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG INHIBITION; DRUG SENSITIVITY; ENTEROCOCCUS; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INFORMATION PROCESSING; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 23644441510     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.05.002     Document Type: Article

References (17)

1. J. Bergeron, M. Ammirati, D. Danley, L. James, M. Norcia, J. Retsema, C.A. Strick, W.-G. Su, J. Sutliffe, and L. Wondrack Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection Antimicrob Agents Chemother 40 1996 2226 2228
2. C. Betriu, I. Rodriguez-Avial, B.A. Sanchez, M. Gomez, and J.J. Picazo Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia J Antimicrob Chemother 50 2002 758 759
3. D.J. Biedenbach, M.L. Beach, and R.N. Jones In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive bloodstream infection isolates and strains producing extended-spectrum β-lactamases Diagn Microbiol Infect Dis 40 2001 173 177
4. E. Cercenado, S. Cercenado, J.A. Gomez, and E. Bouza In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides J Antimicrob Chemother 52 2003 138 139
5. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15 2005 CLSI Wayne (PA)
6. A.C. Fluit, J. Verhoef, F.-J. Schmitz, and The European SENTRY Participants Frequency of isolation and antimicrobial resistance of Gram-negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998 Eur J Clin Microbiol Infect Dis 20 2001 617 625
7. S.K. Fridkin, and R.P. Gaynes Antimicrobial resistance in intensive care units Clin Chest Med 20 1999 303 316
8. S.K. Fridkin, H.A. Hill, and N.V. Volkova The Intensive Care Antimicrobial Resistance Epidemiology (CARE) project hospitals. Temporal change sin prevalence of antimicrobial resistance in 23 U.S. hospitals Emerg Infect Dis 8 2002 697 701
9. T.R. Fritsche, and R.N. Jones Antimicrobial activity of tigecycline (GAR-936) tested against 3,498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections Intern J Antimicrob Agents 24 2004 567 571
10. T.R. Fritsche, J.T. Kirby, and R.N. Jones In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections Diagn Microbiol Infect Dis 49 2004 201 209
11. R.N. Jones Disk diffusion susceptibility test development for the new glycylcycline. GAR-936 Diagn Microbiol Infect Dis 35 1999 249 252
12. D. Nathwani Tigecycline: clinical evidence and formulary positioning Intern J Antimicrob Agents 25 2005 185 192
13. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition. Approved document M7-A6 2003 NCCLS Wayne (PA)
14. P.J. Petersen, P.A. Bradford, W.J. Weiss, T.M. Murphy, P.E. Sum, and S.J. Projan In vitro and in vivo activities of tigecycline (GAR-926), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens Antimicrob Agents Chemother 46 2002 2595 2601
15. J.M. Streit, R.N. Jones, H.S. Sader, and T.R. Fritsche Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001) Intern J Antimicrob Agents 24 2004 111 118
16. Tygacil Product Insert 2005 Wyeth Pharmaceuticals Inc Philadelphia (PA) (June, 2005)
17. G.G. Zhanel, K. Homenuik, and K. Nichol The glycylcyclines: a comparative review with the tetracyclines Drugs 64 2004 63 88